Project Grant R61NS147892
Award Date 9/1/26
Completion Date 8/30/28
Dollars Obligated $635K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded $466,021 to Weill Medical College of Cornell University on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate ACCENT (Acyclovir-Controlled Calcium Entry Neuromodulation Tool), a novel RNA-based platform for selective modulation of L-type voltage-gated calcium channels to treat chronic pain and reduce opioid dependence. The research addresses the clinical problem of...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...
- This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
- The National Institute of Neurological Disorders and Stroke awarded Quiver Bioscience Inc. a Cooperative Agreement for $1,993,248 on April 24, 2026, to develop antisense oligonucleotides targeting Nav1.7 voltage-gated sodium channels as a therapeutic for chronic pain conditions, including neuropathic pain, erythromelalgia, and small fiber neuropathy. The award funds development of a Nav1.7-targeting ASO delivered via intrathecal injection to knock down channel expression in dorsal root...
- The National Institute of Neurological Disorders and Stroke awarded Case Western Reserve University $3,778,614 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate transient selective neural inhibition via photobiomodulation (TSNIP) for chronic knee pain treatment. The research integrates optimized TSNIP parameters into the COSMIIC modular platform—an FDA-qualified system already proven safe for electrical stimulation and sensing in...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- The National Institute of Neurological Disorders and Stroke awarded Weill Medical College of Cornell University $466,125 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to develop and benchmark ACCENT (Acyclovir-Controlled Calcium Entry Neuromodulation Tool), a chemogenetic platform for selective, reversible, and dose-dependent control of L-type calcium channels in neurons using the FDA-approved drug acyclovir. The...
- The National Institute of Neurological Disorders and Stroke (part of the Department of Health and Human Services National Institutes of Health) awarded Oregon Health & Science University $5.363 million on August 18, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to optimize spinal cord stimulation parameters for pain and itch management. The research investigates how epidural spinal cord stimulation engages dorsal horn circuits, specifically targeting neuropeptide Y...